300122 智飞生物
2024/09 - 九个月
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
2020/12
人民币(K¥)
经营活动产生之现金流量净额(3,064,969)8,996,3701,989,0338,507,5923,496,689
投资活动产生之现金流量净额(695,823)(976,599)(1,497,955)(2,019,337)(896,882)
筹资活动产生之现金流量净额684,639(4,293,867)(2,172,647)(3,589,911)(2,113,588)
汇率变动对现金及现金等价物的影响(801)(2,303)17,557(9,661)(4,926)
现金及现金等价物净增加/(减少)(3,076,954)3,723,601(1,664,012)2,888,682481,293
期初现金及现金等价物余额6,339,2902,615,6894,279,7011,391,018909,726
期末现金及现金等价物余额3,262,3366,339,2902,615,6894,279,7011,391,018